The US stock market is experiencing serious volatility as the last couple of months, despite the strong start this year. This deficiency can mainly be attributed to a potentially dangerous trade war between the two biggest economies, the US and China, since February of this year.
Source: Shutterstock From
After President trump has announced plans to impose duties for a period of up to 60 billion dollars. annual imports from China, China, in response, revealing plans to levy duties on American products 128.
This fall-have raised concerns about a possible trade feud between the two countries. In addition, weakness in large caps technician was cited as another reason for this free fall. In addition, the S&P 500 index has registered a decline of 7.7% from the second month of 2018.
Similarly, after solid work in the first two months of the first quarter, in the sphere of illicit trafficking in narcotic drugs and biotech fought in March, probably due to the broader market. In addition, we understand that a few negative updates on the pipeline and regulation sharply reduced growth rates.
Biotechnology industry so far this year, declined 7.4%. In addition, the sector was worse than the 0.6% decline of the S&P 500 index V.
Despite recent market volatility, the buzz of optimism revolves around the rest of the year. Keeping this feeling in mind, we highlight three stocks that may be a good buy for portfolio investors.
Obviously, each stock sports a bullish zacks Rank #1 (strong buy) or # 2 (buy), and there is an increase in stock prices for the last 30 days, despite the market downturn. In addition, the stocks witnessed a positive estimate revision over the period.
Meanwhile, the biotechnology sector is likely to improve as the year progresses. We expect a surge of sales of the new product simultaneously with the growth of demand. In addition, successful innovation and product lines, expanding and strong clinical research outcomes, often with FDA approval, consistently high indicators of basic products, growing demand for drugs especially for rare solutions for the treatment of diseases, the aging population and increasing healthcare costs are some of the factors that should keep the sector on track.
Below are three biotech stocks that meet the above criteria:
Biotech stock that will thrive in the conditions of market instability: Bellerophon Therapeutics Inc (BLPH)
Shares of Bellerophon therapy Inc (Nasdaq:BLPH)grew by 15.9% last month compared to the industry decrease of 6.9%.In addition, the stock has seen the zacks consensus estimate of a loss narrowed 2018 and 2019 49% and 48.7%, respectively, in the last 30 days.
This zacks Rank #2 stockis expected to record growth of 44% this year.
Biotech Stock That Will Thrive In The Conditions Of Market Instability: “Novavax”, Ink. (NVAX)
“Novavax”, Ink. (Nasdaq:NVAX) is a zacks Rank 2. Estimated loss for the company was reduced by 5% by 2018, and 14.9% by 2019 for the last 30 days. Sales and profit growth biotech stock this year is projected at 34.9% and 9.5%, respectively.
Event “Novavax” scored 2.5% last month against the downturn in the industry.
Biotech stock that will thrive in the conditions of market instability: Oncomed Pharmaceuticals Inc (OMED)
Promotions from 2nd place Oncomed Pharmaceuticals Inc (Nasdaq:OMED) rose 9.7% last month, ahead of the industry fall. Consensus is a sign of a loss in 2018 and 2019, has been narrowed 20.7% and 13.7%, respectively, in the last 30 days.
This company is estimated to record sales and profit growth of approximately 32.8% and 7.69%, respectively, in 2018.
You will make a lot of money on the transition to electric vehicles?
Here is another stock idea to consider. Like oil 150 years ago, lithium power may soon shake the world, creating millionaires and improvement of geo-politics. Soon electric vehicles (evs) can be cheaper than gas guzzlers. Some are already up to 265 miles on a single charge.
Prices fall and battery charging stations in a few, one company stands out as the #1 share, according to zacks research.
It’s not the one you think.
To See This Free Ticker >>